Skip to main content
. 2015 Nov 1;25(11):1209–1216. doi: 10.1089/thy.2015.0297

FIG. 3.

FIG. 3.

Thyroid cancer–specific survival and recurrence. (A) Historic thyroid cancer–specific survival for all patients with an initial diagnosis of FTC or HCC between 1965 and 2007. (B) Contemporary thyroid cancer–specific survival after pathology review, stratified by new diagnosis. Median thyroid cancer–specific survival for the FTC group (n = 18) was 19 years ( = 4.7, p = 0.01). Median thyroid cancer–specific survival for the PDC group (n = 5) was eight years (HR = 19.1, p < 0.01). There were no thyroid cancer–specific deaths in the FA or PTC groups. (C) Historic thyroid cancer recurrence for all patients with an initial diagnosis of FTC or HCC between 1965 and 2007. (D) Contemporary thyroid cancer recurrence after pathology review, stratified by new diagnosis. Median time to recurrence for the FTC group (n = 18) was eight years (HR = 22.4, p < 0.01). The single PDC patient that did not present with distant disease recurred after eight years (not shown). There was a single recurrence in the PTC group (n = 24; HR = 0.16, p = 0.09). There were no recurrences in the FA group. HCC, Hürthle cell carcinoma; HR, hazard ratio.